Morningstar
•
Mar 09, 2026
Novo Nordisk A/S: Hims & Hers: Repartnering With Novo Nordisk Removes Legal Overhang and Reshapes Weight-Loss Segment
Summary
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceuti
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Eli Lilly and Company
Apr 30, 2026
•
LLY
Analyst Report: Robinhood Markets Inc
Apr 30, 2026
•
HOOD
Market Digest: BKNG, AMZN, DHI, EAT, CHTR, GNRC, NXPI, HOOD
Apr 30, 2026
•
DHI, NXPI, GNRC, EAT, CHTR, BKNG, HOOD, AMZN
Analyst Report: Robinhood Markets, Inc.
Apr 29, 2026
•
HOOD
HIMS: Lowering target price to $27.00
Apr 29, 2026
•
HIMS
Analyst Profile
Karen Andersen
Sector Strategist
Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is responsible for biotechnology research.Before joining Morningstar in 2005, Andersen received a master’s degree in business administration from Rice University, where she served as senior healthcare analyst for the M.A. Wright Fund and earned the distinction of Jones Scholar. She has scientific research experience in both academia (at Rice University and the University of Queensland in Australia) and industry (at Lexicon Genetics and a subsidiary of Genzyme).Andersen also holds a bachelor’s degree in biochemistry from Rice University, where she graduated magna cum laude. She is a member of Phi Beta Kappa and holds the Chartered Financial Analyst® designation. She ranked first in the biotechnology industry, and had the highest score overall, in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.
